Literature DB >> 15312017

Efficacy of continuous cleansing with teicoplanin on post-CABG methicillin-resistant staphylococcus aureus (MRSA) mediastinitis: report of a case.

Akira Sezai1, Motomi Shiono, Tatsuya Inoue, Mitsumasa Hata, Mitsuru Iida, Tetsuya Niino, Akira Saito, Tsutomu Hattori, Shinji Wakui, Masao Soeda, Nanao Negishi, Yukiyasu Sezai.   

Abstract

The patient was a 48-year-old male who was diagnosed with unstable angina. He had worsening cardiogenic shock during coronary angiography. Emergency coronary artery bypass grafting (CABG) was performed. He had a methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis on day 22 after CABG. Drains were placed in the anterior mediastinum, left thoracic cavity, and abscess cavity, and another drain was placed in the mediastinal space for continuous cleansing with povidone iodine, oxydol. For antibiotics, teicoplanin (TEIC) was administered intravenously and to the local site via the cleansing drain for about one month. No MRSA was detected by culture in discharges from the mediastinal drain. Inflammatory findings were improved, and the patient was discharged and resumed everyday life without recurrence of inflammation as of eight months. Although the number of cases of MRSA mediastinitis is small and accumulation of cases is necessary to investigate therapeutic methods and selection of antibiotics, our department will select closed continuous cleansing and TEIC for antibiotics as the first choice for MRSA mediastinitis, and accumulate cases to investigate its efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312017

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  1 in total

1.  Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections.

Authors:  Wei Wu; Min Liu; Jia-Jing Geng; Mei Wang
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.